AstraZeneca

Karolinska Institutet has appointed Professor Bo Angelin to lead the Integrated Cardio Metabolic Centre (ICMC), a joint initiative with AstraZeneca. Now it is a matter of recruiting scientists to the centre. Stockholm, Sweden, 21-11-2013 — /EuropaWire/ — Bo Angelin is a Professor … Read the full press release →

London, United Kingdom, 10-10-2013 — /EuropaWire/ — AstraZeneca today announced that on 4 October MedImmune, its global biologics research and development arm, completed its acquisition of Amplimmune, a privately-held, US-based biologics company focused on developing novel therapeutics in cancer immunology. As previously announced, … Read the full press release →

London, United Kingdom, 10-10-2013 — /EuropaWire/ — AstraZeneca today announced that the US Court of Appeals for the Federal Circuit (CAFC) lifted a temporary injunction against the US launch of Hanmi’s 505(b)2 NDA esomeprazole strontium product. AstraZeneca’s CAFC appeal of claim construction … Read the full press release →

16-7-2013 — /europawire.eu/ — AstraZeneca today announced that it has entered into an agreement with the University of Cambridge and Cancer Research UK for a two-year collaboration on three pre-clinical and clinical oncology projects. This agreement with world-leading medical research institutions … Read the full press release →

16-7-2013 — /europawire.eu/ — BG Group today announced that, with effect from November 2013, Simon Lowth has been appointed as Chief Financial Officer (CFO) and as an Executive Director. The effective date of the appointments remains to be confirmed and will … Read the full press release →

16-7-2013 — /europawire.eu/ — AstraZeneca today announced that Simon Lowth, Chief Financial Officer (CFO) and Executive Director, will leave the company at the end of October, after the reporting of third quarter results. Simon has been appointed CFO for the BG … Read the full press release →

28-6-2013 — /europawire.eu/ — AstraZeneca today announced that on 27 June 2013 it completed its acquisition of Pearl Therapeutics, a privately held company based in Redwood City, California, focused on the development of inhaled small-molecule therapeutics for respiratory disease.  Upon completion of … Read the full press release →

25-6-2013 — /europawire.eu/ — AstraZeneca today announced that MedImmune, its global biologics research and development arm, and NGM Biopharmaceuticals, Inc. have entered into an exclusive agreement to discover, develop and commercialise novel therapeutics from NGM’s enteroendocrine cell (EEC) programme for the … Read the full press release →

Move brings AstraZeneca’s small molecule and MedImmune’s biologics research and development together at purpose-built facility on Cambridge Biomedical Campus 21-6-2013 — /europawire.eu/ — AstraZeneca today announced that its new UK-based global research and development centre and corporate headquarters will be located … Read the full press release →

20-6-2013 — /europawire.eu/ — AstraZeneca and Bristol-Myers Squibb announced today top-line results of the Phase IV SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin). In this study of adult patients with … Read the full press release →

29-3-2013 — /europawire.eu/ — AstraZeneca och Karolinska Institutet har för avsikt att skapa ett nytt integrerat centrum för translationell forskning kring hjärt-kärlsjukdomar, störningar i ämnesomsättningen och regenerativ medicin. Syftet är att bedriva prekliniska och kliniska studier för att öka förståelsen av … Read the full press release →

Brussels, 31-1-2013 — /europawire.eu/ — Following its competition inquiry into the pharmaceutical sector of 2008/2009 (see IP/09/1098 and MEMO/09/321) the European Commission has issued statements of objections against pharmaceutical companies in three major cases concerning citalopram, an antidepressant, (see IP/12/834), perindopril, a cardio-vascular medicine (see IP/12/835), and … Read the full press release →